Autonomix Medical, Inc. (AMIX)
2.93
+0.03
(+1.03%)
USD |
NASDAQ |
Oct 15, 16:00
2.99
+0.06
(+2.05%)
Pre-Market: 08:37
Autonomix Medical Research and Development Expense (Quarterly) : 1.515M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.515M |
| March 31, 2026 | 1.46M |
| December 31, 2025 | 1.724M |
| September 30, 2025 | 2.367M |
| June 30, 2025 | 1.593M |
| March 31, 2025 | 1.553M |
| December 31, 2024 | 1.044M |
| September 30, 2024 | 1.174M |
| Date | Value |
|---|---|
| June 30, 2024 | 0.954M |
| March 31, 2024 | 0.841M |
| December 31, 2023 | 0.687M |
| September 30, 2023 | 0.4146M |
| June 30, 2023 | 0.368M |
| March 31, 2023 | 0.3192M |
| December 31, 2022 | 0.199M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 7.979M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |
| Baxter International, Inc. | 125.00M |